I'm sitting here thinking about that PR this morning, and I
I'm sitting here thinking about that PR this morning, and I just keep getting more ticked off about it.
Yes, I know that Generex was working on the Swine Flu vaccine in the past and they went through a trial already. But Joe made it perfectly clear, they needed funding to get the Covid Vaccine moving.
If they need funding for that, how in the world are they going to get this Swine Flu Vaccine moving?
I don't know about anyone else, but anyone with any common sense looks at this and sees that they pushed and pushed the need for funding to get a vaccine going and then no news at all coming forward on any funding whatsoever and then Generex comes out with this PR saying they are going to work on ANOTHER vaccine when they haven't even said they were able to get funding on the first vaccine they are working on - COVID19. It's getting harder to believe Joe and Generex.
It's about time they show something real to their shareholders instead of just a PR with words about what they will be doing. They need to show what they HAVE for a change. How about showing some financial means to their shareholders.
Rant over.
3
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....
Continue Reading
Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...
Continue Reading
Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...
Continue Reading
A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...
Continue Reading
A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...
Continue Reading
Top 5 Most Recently Viewed Articles
H&R Block's Engagement at the Northcoast Research 2024 Forum KANSAS CITY, Mo. – H&R Block, Inc. (NYSE: HRB) has exciting news for investors. The company is set to participate in the Northcoast Research 2024 Management Fall Forum. Leading this initiative will be Jeff Jones, the President and Chief Executive Officer, alongside Tiffany Mason, Chief Financial Officer. The...
Continue Reading
About U-KNOCK 2025 U-KNOCK 2025 is a prominent event designed to bring together Korea’s leading creative content companies with global investors. This initiative is backed by the Ministry of Culture, Sports and Tourism of the Republic of Korea and organized by the Korea Creative Content Agency (KOCCA). It celebrates the growing influence of Korean media and aims to...
Continue Reading
Capital One Financial Corp's Third Quarter Performance Capital One Financial Corp. (NYSE: COF) has recently published its third-quarter earnings report, marking a significant achievement with remarkable figures that surpassed analyst projections. The company reported a quarterly earnings of $5.95 per share, outpacing the anticipated $4.37 estimate by an impressive 36%....
Continue Reading
An Unexpected Feather in Hopper's Cap Alright, here we are breaking down another tech nod, but this one's for Hopper—a name that might not strike like the big boys, yet they're making waves. Hopper just snagged a spot on Newsweek's Best Online Platforms for 2026, marking their turf in the Travel & Tourism sector. Though accolades like these appear plenty, they'll...
Continue Reading
Innovative International Acquisition Corp. Faces Stock Decline The stock of Innovative International Acquisition Corp. (ZCAR) has recently dropped to a staggering 52-week low, now trading at just $0.1. This drastic decline serves as a clear indication of the challenges the market is currently facing. The company has witnessed a severe 1-year change of -99.1%, causing...
Continue Reading